Serum tumor necrosis factor activity in inflammatory bowel disease
- PMID: 1517530
- DOI: 10.3109/08923979209005404
Serum tumor necrosis factor activity in inflammatory bowel disease
Abstract
Serum tumor necrosis factor (TNF) levels in 33 patients with inflammatory bowel disease (IBD) were measured by using a sensitive enzyme immunoassay. Four of five Crohn's diseases (CD) and nine of twenty eight ulcerative colitis (UC) had elevated levels of serum TNF. In active CD or UC, a greater fraction of patients studied had significantly increased serum TNF levels (3/3 for CD and 8/11 for UC). Production of TNF by peripheral blood monocytes when stimulated by lipopolysaccharide was also increased in these patients and correlated with their serum TNF levels. These results suggest that TNF may have some pathoetiological meaning in IBD.
Similar articles
-
Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.J Pediatr Gastroenterol Nutr. 2006 May;42(5):479-87. doi: 10.1097/01.mpg.0000221917.80887.9e. J Pediatr Gastroenterol Nutr. 2006. PMID: 16707968
-
Phagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies, and plasma endotoxins in inflammatory bowel disease.Am J Gastroenterol. 2000 Jun;95(6):1495-502. doi: 10.1111/j.1572-0241.2000.02085.x. Am J Gastroenterol. 2000. PMID: 10894586
-
Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease.Gut. 2005 Sep;54(9):1244-53. doi: 10.1136/gut.2004.056309. Epub 2005 May 3. Gut. 2005. PMID: 15870231 Free PMC article.
-
Study of tumor necrosis factor receptor in the inflammatory bowel disease.World J Gastroenterol. 2023 May 14;29(18):2733-2746. doi: 10.3748/wjg.v29.i18.2733. World J Gastroenterol. 2023. PMID: 37274062 Free PMC article. Review.
-
Should biologic agents be stopped before surgery for inflammatory bowel disease?Expert Rev Gastroenterol Hepatol. 2015 Mar;9(3):269-72. doi: 10.1586/17474124.2015.975208. Epub 2014 Nov 4. Expert Rev Gastroenterol Hepatol. 2015. PMID: 25366845 Review.
Cited by
-
Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases.Front Pharmacol. 2019 Jan 28;10:47. doi: 10.3389/fphar.2019.00047. eCollection 2019. Front Pharmacol. 2019. PMID: 30745872 Free PMC article.
-
The Autophagy Protein Pacer Positively Regulates the Therapeutic Potential of Mesenchymal Stem Cells in a Mouse Model of DSS-Induced Colitis.Cells. 2022 Apr 30;11(9):1503. doi: 10.3390/cells11091503. Cells. 2022. PMID: 35563809 Free PMC article.
-
Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease.Mediators Inflamm. 2014;2014:325129. doi: 10.1155/2014/325129. Epub 2014 Jun 17. Mediators Inflamm. 2014. PMID: 25045210 Free PMC article. Review.
-
Chios mastic treatment of patients with active Crohn's disease.World J Gastroenterol. 2007 Feb 7;13(5):748-53. doi: 10.3748/wjg.v13.i5.748. World J Gastroenterol. 2007. PMID: 17278198 Free PMC article. Clinical Trial.
-
Exosomal miR-29b of Gut Origin in Patients With Ulcerative Colitis Suppresses Heart Brain-Derived Neurotrophic Factor.Front Mol Biosci. 2022 Feb 22;9:759689. doi: 10.3389/fmolb.2022.759689. eCollection 2022. Front Mol Biosci. 2022. PMID: 35274002 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources